![US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior](https://becarispublishing.com/cms/10.2217/cer-2021-0226/asset/839401f3-9d0b-41d6-817b-fcd2dc337194/assets/images/large/figure2.jpg)
US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior
![Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression](https://becarispublishing.com/cms/10.2217/cer-2020-0276/asset/abf2e17b-fde1-483a-bbda-e152a257db1d/assets/images/large/figure3b.jpg)
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
![SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire](https://mms.businesswire.com/media/20191219005272/en/764047/4/WebReady480.jpg)
SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire
![Psychedelic Bulletin #125: New Data Boosts Spravato's Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas - Psychedelic Alpha Psychedelic Bulletin #125: New Data Boosts Spravato's Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas - Psychedelic Alpha](https://psychedelicalpha.com/wp-content/uploads/2022/12/New-Spravato-Data-1-1024x576.png)
Psychedelic Bulletin #125: New Data Boosts Spravato's Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas - Psychedelic Alpha
![PDF) Real-world approach to managing dysgeusia following the use of esketamine nasal spray: A case report PDF) Real-world approach to managing dysgeusia following the use of esketamine nasal spray: A case report](https://i1.rgstatic.net/publication/339518189_Real-world_approach_to_managing_dysgeusia_following_the_use_of_esketamine_nasal_spray_A_case_report/links/5e571b03299bf1bdb83e5bc6/largepreview.png)
PDF) Real-world approach to managing dysgeusia following the use of esketamine nasal spray: A case report
![PDF) Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme PDF) Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme](https://i1.rgstatic.net/publication/358690671_Esketamine_nasal_spray_in_patients_with_treatment-resistant_depression_the_real-world_experience_in_the_French_cohort_early-access_programme/links/63743a62431b1f5300a14620/largepreview.png)
PDF) Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
![SPRAVATO ®▽ (esketamine) nasal spray approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder - Hospital Professional News SPRAVATO ®▽ (esketamine) nasal spray approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder - Hospital Professional News](https://hospitalprofessionalnews.ie/wp-content/uploads/2022/03/spravato-esketamine-spray-233x300-1.png)
SPRAVATO ®▽ (esketamine) nasal spray approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder - Hospital Professional News
![NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination | Daily Mail Online NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination | Daily Mail Online](https://i.dailymail.co.uk/1s/2022/09/17/15/62509625-11222317-image-a-18_1663425907764.jpg)
NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination | Daily Mail Online
![US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior](https://becarispublishing.com/cms/10.2217/cer-2021-0226/asset/450a6d84-3f76-4672-921e-81896add8c42/assets/images/large/figure1.jpg)